金吾财讯 | 强生(JNJ)公布,美国食品药品监督管理局 (FDA) 已授予 posdinemab 快速通道资格,posdinemab 是一种针对磷酸化 tau 的单克隆抗体 (mAb),正在2b期“AuTonomy”研究中研究用于治疗早期阿尔茨海默病 (AD) 患者。内部发现的 mAb 已显示出针对接受治疗的 AD 患者脑脊液 (CSF) 中与疾病相关的磷酸化 tau 的潜力,并可阻止非临床疾病模型中 tau 聚集体的形成和扩散。
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
CA
MY
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Tesla's stock rose over 7%! A big policy bonus is coming as the USA plans to loosen regulations on autonomous driving.
Ministry of Foreign Affairs: There have been no consultations or negotiations between China and the United States on the tariff issue, and the U.S. side should not confuse the public.
Seven investment habits of being a "money-making fool".
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
强生:Posdinemab和Tau主动免疫疗法获得美国FDA治疗阿尔茨海默病的快速通道认定
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 312
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report